The Board of Directors of the company has appointed Søren Bregenholt as new Chief Executive Officer (CEO).

He is appointed to strengthen Alligator’s business development activities and clinical progress on an international level, state the company in a press release.

Bregenholt will take up the position on 1 June 2021, succeeding Per Norlén, who will remain in the company. In order to facilitate the transition, Malin Carlsson, Alligator’s COO, is appointed as interim CEO.

Broad global network

“We’re delighted to have Søren onboard. In line with Alligator’s strategy and increased focus on business development and its clinical assets, Alligator is now entering a phase where it will be commercially crucial to further develop and leverage our international network. We are convinced that Søren’s broad global network across pharma, biotech, venture capital and academia, together with his extensive deal experience from both small and large companies, will be invaluable for Alligator as the company continues to assess favorable partnership and out-licensing opportunities, activities which are highly prioritized for Alligator,” says Peter Benson, Chairman of Alligator’s Board of Directors.

Søren Bregenholt has more than 20 years of international experience from operational and strategic leadership positions in global pharma and the biotech industry, states Alligator. He most recently served as CEO and Board Director at Macrophage Pharma Ltd in the UK.

Previous experiences include Corporate Vice President positions at Novo Nordisk A/S between 2010 and 2018, and COO at Symphogen A/S where he worked from 2002 to 2010.

“A very dynamic and respected company in the exciting field of immuno-oncology”

Søren received his PhD from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. He is the author and co-author of more than 45 papers in peer reviewed scientific journals.

“I am really looking forward to the new challenge of leading Alligator Bioscience, a very dynamic and respected company in the exciting field of immuno-oncology. I am impressed by the robust quality of the clinical portfolio as well as the research and development capabilities that has brought the company to this stage. It will be truly exciting to lead and work closely with the competent team at Alligator and take the company further towards clinical and commercial success,” says Søren Bregenholt.